Hospital

Obinutuzumab is a CD20-directed cytolytic antibody used to treat certain types of blood cancer.

High adherence to treatment is a key first step toward better patient outcomes, including sustained disease control or remission.

Analysis results show taking iscosapent ethyl reduces the potential for CV death, coronary revascularization, hospitalization for unstable angina, myocardial infarction, and stroke by 35%.

The companies expect to complete the submission to the FDA for MDD in the first half of 2022 and an associated filing for postpartum depression in 2023.

Sneha Sharma, director, specialty clinical solutions at Magellan Health, discusses some trends in the rare disease space that she recommends pharmacists keep an eye on this year.

Pharmacists are well suited to help patients overcome the barriers that prevent access to therapy regimens.

In addition, YouTube can supplement and inform students’ academic experiences.

Amy Ware, director, specialty clinical solutions at Magellan Health, discusses what it means to be future focused as a pharmacist in the specialty pharmacy field.

Trastuzumab deruxtecan (Enhertu) approved for adult patients with unresectable or metastatic HER2-positive breast cancer who were previously administered an anti–HER2-based regimen.

Tracy Russell, senior director, State Government Affairs at CoverMyMeds, discusses her presentation at Asembia Summit 2022 on legislation aligned with the movement to expand the pharmacist’s role on the care team.

Regardless of the ability to access and dispense products, pharmacists are responsible for getting patients the best care.

Pharmacists can play a more active role in educating patients on tools and resources available to them, enrolling patients in programs, gathering subjective and objective data.

Ray Tancredi, divisional vice president of Specialty Pharmacy, Development & Brand Rx/Vaccine Purchasing at Walgreens, addresses his presentation on the specialty pharmaceutical pipeline, and specifically what approvals pharmacists should look for on the horizon.

But pharmacists can implement medication use systems and collaborate with other health care professionals.

Jayson Slotnik, JD, MPH, partner at Health Policy Strategies, discusses his hopes for the future of value-based contracting and the ideal model for pharmacy’s involvement.

Fecal microbiota transplantation is proving to be an effective treatment for many patients with specific disorders associated with dysbiosis.

Trials results show darolutamide, docetaxel, and androgen deprivation therapy (ADT) reduced the risk of death by 32.5% versus docetaxel/ADT in patients with metastatic hormone-sensitive prostate cancer.

Investigators find that 1 45-minute session of moderate intensity exercise allows more exosomes to deliver the protein, ATP7A, directly to endothelial cells, which can help enable angiogenesis.

This combination improves patient outcomes of vaccine-induced thrombotic thrombocytopenia after a COVID-19 vaccination, according to the results of a case analysis.

Although COVID-19 paused our original plans, we were ultimately able to reach more people than we ever could have via in-person presentations alone.

Patient data are essential to providing coordinator care, but more data also creates heightened risks.

The Voquezna Triple Pak (vonoprazan, amoxicillin, clarithromycin) and Voquezna Dual Pak (vonoprazan, amoxicillin) were previously granted priority review designation by the FDA for H. pylori infection.

Discovery has the potential to also benefit treatment choices, investigators from Georgetown Lombardi Comprehensive Cancer Center say.

Results of a meta-analysis of randomized clinical trials published in JAMA shows improvement in 6 of 8 domains.

For COVID-19 to turn into an endemic, there are a few criteria that must be met.

Legislation allowing pharmacists to prescribe contraceptives is becoming more widespread.

Cytisinicline demonstrated significantly better quit rates than placebo in 6 and 12 week trials.

Vosevi is a fixed-dose combination product containing sofosbuvir, velpatasvir, and voxilaprevir for the re-treatment of adults with chronic hepatitis C.